Genelux (United States)

Genelux (United States)

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Genelux (United States), United States, covering academic research published from 2003 to 2023. Read More.


Open Access Percentage

69%


Total
Publications

136


Total Open
Publications

94


Total
Citations

4.7K


Open Access
Percentage

69%


Total
Publications

136


Total Open
Publications

94


Total
Citations

4.7K

Wikipedia

Website

download

Breakdown

14% 43% 12% 31%

Publisher Open

14%

Both

43%

Other Platform Open

12%

Closed

31%

Percentage of Open Access over time

200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0246810121416182022Total Publications
200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

64%OA Journal

OA Journal 64%

49

Hybrid 8%

6

No Guarantees 28%

22

Other Platform Open

Domain 62%

46

Other Internet 45%

33

Institution 28%

21

Public 11%

8

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
45
DOI
Other Internet
34
University of Würzburg
Institution
16
Figshare
Public
8
Europe PMC
Domain
6
University of Milano-Bicocca
Institution
1
University of Milan
Institution
1
University of Genoa
Institution
1
University College of Arts Crafts and Design
Institution
1
Universidad de Granada
Institution
1
1 / 2

Data updated 18 August 2025

Share

Share

Share